BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).

被引：35

作者：

Luke, Jason J.

Tabernero, Josep

Joshua, Anthony

Desai, Jayesh

Varga, Andrea I.

Moreno, Victor

Gomez-Roca, Carlos A.

Markman, Ben

De Braud, Filippo G.

Patel, Sandip Pravin

Carlino, Matteo S.

Siu, Lillian L.

Curigliano, Giuseppe

Liu, Zhaohui

Ishii, Yuko

Wind-Rotolo, Megan

Basciano, Paul Andrew

Azrilevich, Alex

Gelmon, Karen A.

机构：

[1] Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA

[2] Vall dHebron Univ Hosp, Barcelona, Spain

[3] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia

[4] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[5] Royal Melbourne Hosp, Melbourne, Vic, Australia

[6] Gustave Roussy Canc Campus, Villejuif, France

[7] Hosp Univ Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain

[8] Inst Univ Canc Toulouse Oncopole, Toulouse, France

[9] Monash Hlth, Melbourne, Vic, Australia

[10] Monash Univ, Melbourne, Vic, Australia

[11] Fdn IRCCS Ist Nazl Tumori Milano, Dept Med Oncol, Milan, Italy

[12] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA

[13] Melanoma Inst Australia, Westmead Hosp, Sydney, NSW, Australia

[14] Melanoma Inst Australia, Blacktown Hosp, Sydney, NSW, Australia

[15] Univ Sydney, Sydney, NSW, Australia

[16] Princess Margaret Canc Ctr, Toronto, ON, Canada

[17] Univ Milan, Ist Europeo Oncol, IRCCS, Milan, Italy

[18] Bristol Myers Squibb, Princeton, NJ USA

[19] Univ British Columbia, BC Canc Agcy, Vancouver, BC, Canada

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 07期

关键词：

D O I：

10.1200/JCO.2019.37.7_suppl.358

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

358

引用

页数：2